氯胺酮治疗难治性头痛:回顾性分析
随访1和2的持续应答率分别为40%(平均38.1天)和39%(平均101.3天),不良反应轻且两组间无差异。
要点
- 连续静脉氯胺酮治疗5天可使77%的难治性头痛患者获得即刻疼痛缓解。
- 持续应答率在随访1和2分别为40%和39%,最大改善平均在治疗4.56天出现。
- 不良反应轻且应答者与非应答者发生率无差异,最大平均氯胺酮速率为65.2±2.8 mg/h。
核心结论
- 氯胺酮与许多难治性头痛患者的短期镇痛相关,且不良反应可耐受。
研究设计与样本
- 回顾性研究纳入61例因难治性头痛住院接受5天连续静脉氯胺酮治疗的患者。
主要发现
- 最大改善出现在治疗平均4.56天时。
- 持续应答率在随访1(平均38.1天)为40%,在随访2(平均101.3天)为39%。
- 最大平均氯胺酮速率为65.2±2.8 mg/h(0.76 mg/kg每小时),应答者与非应答者间无差异。
- 不良反应在应答者与非应答者中发生率相等且轻微。
关键数值与推荐
- 即刻应答定义为数字评定量表(0-10)从开始到出院最终疼痛下降≥2分。
- 持续应答定义为在随访1和2时维持2分改善。
临床怎么用
- 对于难治性头痛患者,可考虑连续静脉氯胺酮治疗5天以短期缓解疼痛。
- 治疗期间应每日评估疼痛和不良反应,最大平均速率可达65.2±2.8 mg/h。
局限性
- 回顾性研究设计,样本量61例,需前瞻性研究确认结果并阐明应答者特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The burden of chronic headache disorders in the United States is substantial. Some patients are treatment refractory. Ketamine, an N-methyl-D-aspartate antagonist, provides potent analgesia in subanesthetic doses in chronic pain, and limited data suggest it may alleviate headache in some patients. METHODS: We performed a retrospective study of 61 patients admitted over 3 years for 5 days of intravenous therapy that included continuous ketamine to determine responder rate and patient and ketamine infusion characteristics. Pain ratings at 2 follow-up visits were recorded. An immediate responder was a patient with decrease of 2 points or greater in the numerical rating scale (0-10) from start to final pain in the hospital. Sustained response at office visits 1 and 2 was determined based on maintaining the 2-point improvement at those visits. Patients were assessed daily for pain and adverse events (AEs). RESULTS: Forty-eight (77%) of the 61 patients were immediate responders. There were no differences regarding demographics, opioid use, or fibromyalgia between immediate responders and nonresponders. Maximum improvement occurred 4.56 days (mean) into treatment. Sustained response occurred in 40% of patients at visit 1 (mean, 38.1 days) and 39% of patients at visit 2 (mean, 101.3 days). The mean maximum ketamine rate was 65.2 ± 2.8 mg/h (0.76 mg/kg per hour). Ketamine rates did not differ between groups. Adverse events occurred equally in responders and nonresponders and were mild. CONCLUSIONS: Ketamine was associated with short-term analgesia in many refractory headache patients with tolerable adverse events. A prospective study is warranted to confirm this and elucidate responder characteristics.
引用
- Schwenk ES, Dayan AC, Rangavajjula A, et al. Ketamine for Refractory Headache: A Retrospective Analysis. Reg Anesth Pain Med. 2018. PMID: 29923953. doi:10.1097/AAP.0000000000000827
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。